

# **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**DIVISION OF HEALTH CARE FINANCING AND POLICY** Helping people. It's who we are and what we do.



JD MPH

## Silver State Scripts Board Meeting Minutes

Date of Meeting:	Thursday, September 26, 2024, at 1:00 PM
Name of Organization:	The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Ag	enda Item	Record	Notes		
1.	Closed Executive Session				
1.	a. Call to Order and Roll Call	Chairperson Mark Decerbo called the m September 26, 2024. Chairperson Decerbo took the roll. Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm. D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD	Present	Absent	<ul> <li>DHCFP Staff Present were as follows:</li> <li>Brown, Antonio, Chief of Pharmacy &amp; DME</li> <li>Duncan, Keiko, PharmD, Medicaid Pharmacy Director</li> <li>Flowers, Ellen, Social Services Program Specialist II</li> <li>Palomino, Bonnie, Pharmacy Services Manager</li> <li>Vannucci, Jessica, DME Supervisor</li> </ul>
					<ul> <li>Driscoll, Lauren, Deputy Attorney General</li> </ul>

		<ul> <li>NMAP Staff Present were as follows:</li> <li>Johnson, Tory, Health Program Manager II</li> <li>Prime Staff Present were as follows:</li> <li>Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>Kim, James, Pharm.D., Dir. Clinical Account Services</li> <li>Deoliveira, Brittany, Pharm.D., Clinical Account Manager</li> <li>Martinez, Chris, Sr. Business Analyst</li> <li>Perez, Melissa, Sr. Business Analyst</li> </ul>
b. Financial Review of Drug Classes with Proposed Changes	<ul> <li>Chairperson Decerbo directed Dr. Brittany Deoliveira to proceed with the Financial Review of Drug classes with proposed changes up for review.</li> <li>Dr. Deoliveira reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting.</li> <li>Dr. Deoliveira presented the financial review of the established drug classes being reviewed due to the release of new drugs, noting the products with proposed changes in PDL status.         <ul> <li>Miscellaneous Heart Failure Agents</li> <li>Phosphodiesterase Type 4 Inhibitors</li> <li>Erythropoiesis-Stimulating Agents</li> </ul> </li> </ul>	

	Movement Disorders	
	Targeted Immunomodulator	
Dr.	Deoliveira presented the financial review of the established drug	
clas	ses being reviewed due to the release of new generics, noting the	
pro	ducts with proposed changes in PDL status.	
	Incretin Mimetics and Combinations	
Dr.	Deoliveira presented the financial review of the established drug	
clas	ses with proposed changes, noting the products with proposed	
cha	nges in PDL status.	
	• Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin	
	Non-ergot Dopamine Agonists	
	Ophthalmic Quinolones	
	Second-Generation Cephalosporins	
	Bisphosphonates	
Dr.	Deoliveira presented the financial review of the established drug	
	ses without proposed changes, noting the products with proposed	
cha	nges in PDL status.	
	Analgesics	
	Antihistamines	
	Anti-infective Agents	
	Autonomic Agents	
	Biologic Response Modifiers	
	Cardiovascular Agents	
	Dermatological Agents	
	Electrolytes and Renal Agents	
	Gastrointestinal Agents	
	Genitourinary Agents	
	Hematological Agents	
	Hormones and Hormone Modifiers	
	Monoclonal Antibodies for the Treatment of Respiratory	

	Conditions Musculoskeletal Agents Neurological Agents Ophthalmic Agents Otic Agent Psychotropic Agents Respiratory Agents Toxicology Agents Appendix A		
2. Open Public Meeting a. Call to Order and Roll Call	Chairperson Decerbo called the meeting September 26, 2024. A quorum was present. Chairperson Decerbo took the roll. Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm. D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD	Present Absent   Absent Image: Constraint of the sector of the sect	<ul> <li>DHCFP Staff Present were as follows:         <ul> <li>Brown, Antonio, Chief of Pharmacy &amp; DME</li> <li>Duncan, Keiko, PharmD, Medicaid Pharmacy Director</li> <li>Flowers, Ellen, Social Services Program Specialist II</li> <li>Palomino, Bonnie, Pharmacy Services Manager</li> <li>Vannucci, Jessica, DME Supervisor Driscoll, Lauren, Deputy Attorney General</li> </ul> </li> <li>NMAP Staff Present were as follows:         <ul> <li>Johnson, Tory, Health Program Manager II</li> </ul> </li> </ul>

					<ul> <li>Magellan (Prime) Staff Present were as follows:</li> <li>Mishra, Raj, Pharm.D., Clinical Account Manager</li> <li>Kim, James, Pharm.D., Dir. Clinical Account Services</li> <li>Deoliveira, Brittany, Pharm.D., Clinical Account Manager</li> <li>Martinez, Chris, Sr. Business Analyst</li> <li>Perez, Melissa, Sr. Business Analyst</li> <li>The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured</li> </ul>
b. Approval for previous Meeting Minutes from June 20, 2024.	Chairperson Decerbo moved to app Board Member Elizabeth Gonzalez			-	
	A vote was taken, and the results wattendance (in favor, against, and a				1
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
	<ul> <li>Joseph Adashek, MD</li> </ul>	$\mathbf{X}$			
	Mark Crumby, Pharm.D.	$\mathbf{X}$			
	Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			

c. Public Comments	<ul> <li>Sapandeep Khurana, MD X I I</li> <li>Isabella Niezborala, Pharm.D. X I</li> <li>Leana Ramirez, Pharm.D. X I</li> <li>Aditi Singh, MD I</li> <li>Z</li> <li>Telephonic and web comment was called for, and the phone lines were opened.</li> <li>No Public comment was provided.</li> </ul>	
d. Status Update by DHCFP	<ul> <li>Chief of Pharmacy &amp; DME, Antonio Brown, provided an announcement.</li> <li>So first I just wanted to bid farewell to our Silver State Scripts Board member Doctor Izabela Niezborala who's last meeting is today, Doctor Izabela Niezborala has been an invaluable member of the Silver State Scripts Board since February of 2022. Helping us achieve our mission to provide quality health care services and to low-income individuals and families in Nevada. So please join me in welcoming all the best and we wish you the best in your future endeavors and on behalf of Nevada and all the people that we serve. Thank you for everything you have done, and we hope that we cross paths in the future as well. And with that, I just want to mention that the Silver State script board is also recruiting and if you are interested you could send your CV to rxinfo@dhcfp.nv.gov.</li> <li>The last announcement that I want to make is we recently had a public hearing on Nevada Medicaid Services Manual Chapter 1200 to adopt the changes that were approved and voted on the July 27th, 2024, Drug Utilization Review meeting. Those changes will be taking effect as of September 30 and if you want any additional details, you can always visit our web page at dhcfp.nv.gov.</li> </ul>	
e. Status Update by NMAP	<ul> <li>Health Program Manager, Tory Johnson, provided an announcement.</li> <li>There is no update for NMAP today.</li> </ul>	

3. Clinical Present	ations						
and possible	Action: Discussion e adoption of ous Heart Failure						
i. <u>Public</u>	<u>comment</u>	Telephonic and web opened.	comment was c	alled fo	or, and	the phone lines v	were
		No public comment v	was provided.				
presen	ass review tation by an (Prime).	Dr. Deoliveira discuss new dosage form Ent ivabradine tablet. She and noted the indicat Dr. Deoliveira recommender therapeutically equiv	tresto <sup>®</sup> sprinkle e presented the tion, mechanisr mended the Bo	capsule availat n of act	e and t pility w ion, an	he new generic ithin the drug cla id efficacy studie	ISS S.
action approv clinical	sion by Board and by Board to re /therapeutic lency of agents in	Board Member Josep and therapeutically e Board Member Gonz A vote was taken, and attendance (in favor,	equivalent as pro alez seconded t d the results we	esenteo the mot ere as fo	l by Ma ion. Ilows f	agellan (Prime), a From members in	ind
		<ul> <li>Mark Decerbo, Pha</li> <li>Kate Ward, Pharm.</li> <li>Joseph Adashek,</li> <li>Mark Crumby, Ph</li> <li>Elizabeth Gonzale</li> <li>Sapandeep Khura</li> </ul>	D., Vice Chair MD narm.D. ez, Pharm.D.	Yes ⊠ □ ⊠ ⊠	No 	Abst.	

	Isabella Niezborala, Pharm.D.	$\boxtimes$			
	<ul> <li>Leana Ramirez, Pharm.D.</li> </ul>				
	<ul> <li>Aditi Singh, MD</li> </ul>				
iv. Presentation of	<ul> <li>Additisingh, MD</li> <li>Dr. Deoliveira recommended adding</li> </ul>				tho
recommendations for PDL	PDL as non-preferred. She also reco	-	•	•	
inclusion by Magellan	tablet and suspension from preferre			-	
(Prime).	generic ivabradine to preferred.				
v. Discussion by Board and	Board Member Adashek moved to a	approve	the pr	oposed changes as	s
action by Board for	presented by Magellan (Prime) and	Board I	Nembe	er Sapandeep Khur	ana
approval of drugs for inclusion on the PDL.	seconded the motion.				
inclusion on the r DL.	A vote was taken, and the results w	ere as fo	ollows	from members in	
	attendance (in favor, against, and a				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
	<ul> <li>Joseph Adashek, MD</li> </ul>	$\boxtimes$			
	Mark Crumby, Pharm.D.	$\boxtimes$			
	• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	Sapandeep Khurana, MD	$\boxtimes$			
	Isabella Niezborala, Pharm.D.	$\boxtimes$			
	• Leana Ramirez, Pharm.D.	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	
<b>B.</b> For Possible Action: Discussion					
and possible adoption of					
Phosphodiesterase Type 4 Inhibitors.					
minbitors.					
i. Public comment	Telephonic and web comment was	called for	or, and	the phone lines w	vere
	opened.				

		No public comment was provided.				
ii.	Drug class review presentation by Magellan (Prime).	Dr. Deoliveira discussed Ohtuvayre class. She presented the availability indication, mechanism of action, ar	within	the dru	ug class and noted t	-
		Dr. Deoliveira recommended the Be therapeutically equivalent.	oard cor	nsider t	he class clinically ar	nd
iii.	Discussion by Board and action by Board to approve clinical/therapeutic	Chairperson Decerbo moved to acc therapeutically equivalent as prese Member Adashek seconded the mo	nted by otion.	Magel	lan (Prime) and Boa	rd
	equivalency of agents in class.	A vote was taken, and the results w attendance (in favor, against, and a				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	$\mathbf{X}$			
		Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
		<ul> <li>Joseph Adashek, MD</li> </ul>	$\mathbf{X}$			
		Mark Crumby, Pharm.D.	$\mathbf{X}$			
		• Elizabeth Gonzalez, Pharm.D.	$\mathbf{X}$			
		Sapandeep Khurana, MD	$\boxtimes$			
		Isabella Niezborala, Pharm.D.	$\boxtimes$			
		• Leana Ramirez, Pharm.D.	$\mathbf{X}$			
		<ul> <li>Aditi Singh, MD</li> </ul>			$\boxtimes$	
iv.	Presentation of recommendations for PDL inclusion by Magellan (Prime).	Dr. Deoliveira recommended addin preferred. She also recommended to read as Phosphodiesterase Type	changin	, g the n	ame of this drug cla	SS

v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Chairperson Decerbo moved to approve the proposed changes as presented by Magellan (Prime) and Board Member Adashek seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	
<b>C.</b> For Possible Action: Discussion	YesNoAbst.Mark Decerbo, Pharm.D., ChairIIKate Ward, Pharm.D., Vice ChairIIJoseph Adashek, MDIIMark Crumby, Pharm.D.IIElizabeth Gonzalez, Pharm.D.IISapandeep Khurana, MDIIIsabella Niezborala, Pharm.D.IILeana Ramirez, Pharm.D.IIAditi Singh, MDII	
and possible adoption of Erythropoiesis-Stimulating Agents.		
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii. Drug class review presentation by Magellan (Prime).	<ul> <li>Dr. Deoliveira discussed Vafseo<sup>®</sup>, a new product within this drug class, and Reblozyl<sup>®</sup>. She presented the availability within the drug class and noted the indication, mechanism of action, and efficacy studies.</li> <li>Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.</li> </ul>	

iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	therapeutically equivalent as presen Member Gonzalez seconded the mo A vote was taken, and the results we	Board Member Adashek moved to accept the class as clinically and herapeutically equivalent as presented by Magellan (Prime) and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in ttendance (in favor, against, and abstentions where applicable):				
		<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D.</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D.</li> <li>Leana Ramirez, Pharm.D.</li> <li>Aditi Singh, MD</li> </ul>	Yes	No	Abst.  Abst.  A		
iv.	Presentation of recommendations for PDL inclusion by Magellan (Prime).	Dr. Deoliveira recommended adding preferred agents to the PDL.	g Vafse	o <sup>®</sup> and	Reblozyl <sup>®</sup> as non-		
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to a presented by Magellan (Prime) and the motion. A vote was taken, and the results we attendance (in favor, against, and a	Board I	Membe ollows	er Gonzalez seconded from members in		
			Yes	No	Abst.		

	Mark Decerbo, Pharm.D., Chair 🛛 🗌 🗌	
	Kate Ward, Pharm.D., Vice Chair	
	• Joseph Adashek, MD 🛛 🗆	
	• Mark Crumby, Pharm.D. 🛛 🗆 🗆	
	• Elizabeth Gonzalez, Pharm.D. 🛛 🗆 🗆	
	• Sapandeep Khurana, MD 🛛 🗌	
	• Isabella Niezborala, Pharm.D. 🛛 🗌 🗌	
	• Leana Ramirez, Pharm.D. 🛛 🗌 🗌	
	• Aditi Singh, MD 🗌 🗌 🛛	
<b>D.</b> For Possible Action: Discussion		
and possible adoption of		
Movement Disorders.		
i Dublic Commont	Talaahan'a and wah aanmant waa cellad fan and tha nhana lines waa	
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were	
	opened.	
	No public comment was provided.	
ii. Drug class review	Dr. Deoliveira presented the new product in this class, the Ingrezza®	
presentation by	sprinkle capsule. She also presented the availability within the drug	
Magellan (Prime).	class and noted the indication, mechanism of action, and efficacy	
	studies.	
	Dr. De sliveire recorded the Decud consider the class divisely and	
	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.	
iii. Discussion by Board and	Board Member Adashek moved to accept the class as clinically and	
action by Board to	therapeutically equivalent as presented by Magellan (Prime) and Board	
approve	Member Khurana seconded the motion.	
clinical/therapeutic		
equivalency of agents in	A vote was taken, and the results were as follows from members in	
class.	attendance (in favor, against, and abstentions where applicable):	

		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair		No □	Abst.	
	<ul> <li>Kate Ward, Pharm.D., Vice Chair</li> </ul>			$\square$	
	<ul> <li>Joseph Adashek, MD</li> </ul>				
	<ul> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D.</li> </ul>				
		$\boxtimes$			
	• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
	Sapandeep Khurana, MD	$\boxtimes$			
	Isabella Niezborala, Pharm.D.	$\boxtimes$			
	Leana Ramirez, Pharm.D.	$\boxtimes$			
iv. Presentation of	Aditi Singh, MD     Dr. Deoliveira recommended adding				
recommendations for PDL inclusion by Magellan (Prime).	capsule as a preferred product on the preferred Ingrezza® product that the these two products. She also recombination pack from non-preferred to the theory of the terms of terms of the terms of te	is is the mendeo	capsul d movi	le to differentiate	nt
<ul> <li>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</li> </ul>	Board Member Gonzalez moved to presented by Magellan (Prime) and the motion. A vote was taken, and the results we attendance (in favor, against, and a	Board N ere as fo	vembe ollows	er Adashek secondeo from members in	
		Yes	No	Abst.	
	• Mark Decerbo, Pharm.D., Chair	$\mathbf{X}$			
	• Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
	• Joseph Adashek, MD	$\mathbf{X}$			
	• Mark Crumby, Pharm.D.	$\mathbf{X}$			
	• Elizabeth Gonzalez, Pharm.D.	$\mathbf{X}$			
	Sapandeep Khurana, MD	$\mathbf{X}$			
	• Isabella Niezborala, Pharm.D.	$\mathbf{X}$			
	• Leana Ramirez, Pharm.D.	$\boxtimes$			
	Aditi Singh, MD			$\boxtimes$	

<ul> <li>For Possible Action: Discussion and possible adoption of Targeted Immunomodulator.</li> </ul>					
i. <u>Public Comment</u>	Telephonic and web comment was opened.	called fo	r, and	the phone lines were	
	Public comment was provided by A scientific account lead with Johnson		-		
	Public comment was provided by N	1elinda T	urking	ton, liaison with UCB.	
	Public comment was provided by V Medical Affairs.	in D pha	rmacis	t, with Monteva	
ii. Drug class review presentation by Magellan (Prime).	Dr. Deoliveira presented the availab the indication, mechanism of action	, and eff	icacy s	tudies.	
	Dr. Deoliveira recommended the Bo therapeutically equivalent.	bard cons	sider t	ne class clinically and	
<ul> <li>iii. Discussion by Board and action by Board to approve clinical/therapeutic</li> </ul>	Board Member Adashek moved to therapeutically equivalent as prese Member Gonzalez seconded the m	nted by I		-	
equivalency of agents in class.	A vote was taken, and the results w attendance (in favor, against, and a				
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
	<ul><li>Joseph Adashek, MD</li><li>Mark Crumby, Pharm.D.</li></ul>	$\boxtimes$			

iv. Presentation of recommendations for PDL inclusion by Magellan (Prime).	<ul> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D.</li> <li>Leana Ramirez, Pharm.D.</li> <li>Aditi Singh, MD</li> <li>Dr. Deoliveira recommended adding a aaty, adalimumab-adbm, adalimumal Omvoh®, Simlandi® and Velsipity® as recommended moving Taltz® from pr</li> </ul>	⊠ ⊠ □ adalimun b-ryvk, Al non-pref	brilad erred	da <sup>®</sup> , Bimzelx <sup>®</sup> , d. She as	
v. Board Member Comments	Dr. Leana Ramirez provided a comm Chairperson Decerbo provided a cor				
vi. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Gonzalez moved to a presented by Magellan (Prime) and non-preferred under this drug class, under the multiple sclerosis (MS) dr drug's indications. Board Member A	also prop as this d ug class,	osed rug is to ali	l adding Zeposia® a s already on the PE gn with both of thi	is DL
	A vote was taken, and the results we attendance (in favor, against, and al				
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D.</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D.</li> </ul>		No	Abst. □ □ □ □	

	• Leana Ramirez, Pharm.D.	X			
	Aditi Singh, MD			$\boxtimes$	
<ul> <li>For Possible Action: Discussion and possible adoption of Incretin Mimetics and Combinations.</li> </ul>					
i. <u>Public Comment</u>	Telephonic and web comment was opened.	called fo	or, and	the phone lines	s were
	No public comment was provided.				
<ul><li>ii. Drug class review</li><li>presentation by Magellan</li><li>(Prime).</li></ul>	Dr. Deoliveira recommended the Bo therapeutically equivalent.	oard cor	nsider t	he class clinical	ly and
<ul> <li>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</li> </ul>	Board Member Adashek moved to a therapeutically equivalent presente Member Khurana seconded the mo A vote was taken, and the results we attendance (in favor, against, and al	d by Ma tion. ere as fo	agellan ollows	(Prime) and Bo rom members i	ard
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D.</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D.</li> <li>Leana Ramirez, Pharm.D.</li> <li>Aditi Singh, MD</li> </ul>	Yes ⊠ ⊠ ⊠ ⊠ ⊠ ⊠ ≅	No	Abst. □ □ □ □ □ □ □	

i	iv. Presentation of recommendations for PDL inclusion by Magellan (Prime).	Dr. Deoliveira recommends keepin adding its generic liraglutide as nor removing Adlyxin® from the PDL du discontinued.	n-preferi	ed. Als	o recommend	
	<ul> <li>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</li> </ul>	Chairperson Decerbo moved to app presented by Magellan (Prime) and the motion. A vote was taken, and the results w attendance (in favor, against, and a	l Board I vere as fo	Membe	er Gonzalez seconde from members in	d
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
		Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
		<ul> <li>Joseph Adashek, MD</li> </ul>	$\boxtimes$			
		Mark Crumby, Pharm.D.	$\boxtimes$			
		• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$			
		Sapandeep Khurana, MD	$\boxtimes$			
		• Isabella Niezborala, Pharm.D.	$\boxtimes$			
		• Leana Ramirez, Pharm.D.	$\boxtimes$			
		Aditi Singh, MD			$\boxtimes$	
_	For Possible Action: Discussion and possible adoption of Dipeptidyl Peptidase-4 Inhibitors and Combinations with Metformin.					
	i. <u>Public Comment</u>	Telephonic and web comment was opened.	called for	or, and	the phone lines we	e

	No public comment was provided.
<ul><li>ii. Drug class review</li><li>presentation by Magellan</li><li>(Prime).</li></ul>	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.
<ul> <li>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</li> </ul>	Board Member Adashek moved to accept the class as clinically and therapeutically equivalent as presented by Magellan (Prime) and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):
	Yes No Abst.   Mark Decerbo, Pharm.D., Chair I   Kate Ward, Pharm.D., Vice Chair I   Joseph Adashek, MD I   Mark Crumby, Pharm.D. I   Elizabeth Gonzalez, Pharm.D. I   Sapandeep Khurana, MD I   Isabella Niezborala, Pharm.D. I   Leana Ramirez, Pharm.D. I   Aditi Singh, MD I
<ul><li>iv. Presentation of recommendations for PDL inclusion by Magellan (Prime).</li></ul>	Dr. Deoliveira recommends removing Kazano <sup>®</sup> , Nesina <sup>®</sup> and Oseni <sup>®</sup> from the PDL as these products have been discontinued.
<ul> <li>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</li> </ul>	Chairperson Decerbo moved to approve the proposed changes as presented by Magellan (Prime) and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in

	attendance (in favor, against, and al	bstentio	ons wh	ere applicable):	
	<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D.</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> </ul>	Yes	No          	Abst.	
	<ul> <li>Isabella Niezborala, Pharm.D.</li> <li>Leana Ramirez, Pharm.D.</li> <li>Aditi Singh, MD</li> </ul>				
<ul> <li>H. For Possible Action: Discussion and possible adoption of Non- ergot Dopamine Agonists.</li> </ul>				_	
i. <u>Public Comment</u>	Telephonic and web comment was opened. No public comment was provided.	called fo	or, and	the phone lines were	
<ul><li>ii. Drug class review</li><li>presentation by Magellan</li><li>(Prime).</li></ul>	Dr. Deoliveira recommended the Bo therapeutically equivalent.	oard cor	he class clinically and		
<ul> <li>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</li> </ul>	Board Member Adashek moved to a therapeutically equivalent as preser Member Gonzalez seconded the mo A vote was taken, and the results we attendance (in favor, against, and al	nted by otion. ere as fo	Magel ollows	lan (Prime) and Board from members in	
		Yes	No	Abst.	

	Mark Decerbo, Pharm.D., Chair	$\mathbf{X}$				
	• Kate Ward, Pharm.D., Vice Chair			$\boxtimes$		
	<ul> <li>Joseph Adashek, MD</li> </ul>	$\mathbf{X}$				
	Mark Crumby, Pharm.D.	$\boxtimes$				
	• Elizabeth Gonzalez, Pharm.D.	$\mathbf{X}$				
	<ul> <li>Sapandeep Khurana, MD</li> </ul>	$\mathbf{X}$				
	Isabella Niezborala, Pharm.D.	$\mathbf{X}$				
	• Leana Ramirez, Pharm.D.	$\boxtimes$				
	<ul> <li>Aditi Singh, MD</li> </ul>			$\boxtimes$		
iv. Presentation of	Dr. Deoliveira recommended adding	-			-	
recommendations for PDL	rasagiline as non-preferred. She also					
inclusion by Magellan	ER <sup>®</sup> from preferred to non-preferre pramipexole ER to non-preferred. S			-	-	
(Prime).	Kynmobi <sup>®</sup> from the PDL as this drug				-	
		, 1105 60		ontinue		
v. Discussion by Board and	Chairperson Decerbo moved to app	rove th	e prop	osed ch	anges as	
action by Board for	presented by Magellan (Prime) and	Board I	Membe	er Adash	nek seconded	
approval of drugs for	the motion.					
inclusion on the PDL.						
	A vote was taken, and the results w					
	attendance (in favor, against, and a	bstentio	ons wh	ere app	licable):	
		Vee	Ne	1 h at		
	• Mark Deserbe Dharm D. Chair	Yes	No □	Abst.		
	Mark Decerbo, Pharm.D., Chair					
	Kate Ward, Pharm.D., Vice Chair					
	Joseph Adashek, MD	$\boxtimes$				
	Mark Crumby, Pharm.D.	$\boxtimes$				
	• Elizabeth Gonzalez, Pharm.D.	$\boxtimes$				
	Sapandeep Khurana, MD	$\boxtimes$				
	<ul> <li>Isabella Niezborala, Pharm.D.</li> </ul>	$\times$				

	<ul><li>Leana Ramirez, Pharm.D.</li><li>Aditi Singh, MD</li></ul>				
<ul> <li>For Possible Action: Discussion and possible adoption of Ophthalmic Quinolones.</li> </ul>					
i. <u>Public Comment</u>	Telephonic and web comment was opened.	called fo	r, and	the phone lines were	
	No public comment was provided.				
<ul><li>ii. Drug class review</li><li>presentation by Magellan</li><li>(Prime).</li></ul>	Dr. Deoliveira recommended the Bo therapeutically equivalent.	oard cons	sider t	he class clinically and	
<ul> <li>iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.</li> </ul>	Board Member Adashek moved to a therapeutically equivalent as presen Member Gonzalez seconded the mo A vote was taken, and the results we attendance (in favor, against, and a	nted by Notion. Pere as fo	/lagel	lan (Prime) and Board from members in	
		Yes	for, and the phone lines were         for, and the phone lines were         onsider the class clinically and         the class as clinically and         y Magellan (Prime) and Board         follows from members in         ions where applicable):		
	• Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
	• Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
	<ul> <li>Joseph Adashek, MD</li> </ul>	$\boxtimes$			
	• Mark Crumby, Pharm.D.	$\boxtimes$			
	• Elizabeth Gonzalez, Pharm.D.	$\mathbf{X}$		—	
	Sapandeep Khurana, MD	$\boxtimes$			
	Isabella Niezborala, Pharm.D.	$\boxtimes$			
	Leana Ramirez, Pharm.D.				
	Aditi Singh, MD				

	<ul><li>iv. Presentation of recommendations for PDL inclusion by Magellan (Prime).</li></ul>	Dr. Deoliveira recommended movir to non-preferred, and adding its ge Vigamox <sup>®</sup> ) to preferred. She also re (generic for Moxeza <sup>®</sup> ) as non-prefe the PDL as this product has been di ophthalmic levofloxacin will be rem participating in the Medicaid Drug	neric me comme rred and scontinu	oxiflox ended k d remc ued. Sh om the	acin (generic for keeping moxifloxacin oving Moxeza® from he also stated that PDL as it is no longer	
	<ul> <li>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</li> </ul>	Chairperson Decerbo moved to app presented by Magellan (Prime) and the motion. A vote was taken, and the results w	Board I	Membe	er Adashek seconded	
		attendance (in favor, against, and a				
			Yes	No	Abst.	
		Mark Decerbo, Pharm.D., Chair	$\boxtimes$			
		Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
		<ul> <li>Joseph Adashek, MD</li> </ul>	$\mathbf{X}$			
		Mark Crumby, Pharm.D.	$\mathbf{X}$			
		• Elizabeth Gonzalez, Pharm.D.	X			
		Sapandeep Khurana, MD	$\mathbf{X}$			
		Isabella Niezborala, Pharm.D.	$\mathbf{X}$			
		• Leana Ramirez, Pharm.D.	$\mathbf{X}$			
		Aditi Singh, MD			$\boxtimes$	
J.	For Possible Action: Discussion and possible adoption of Second-Generation Cephalosporins.					
	i. Public Comment	Telephonic and web comment was	called f	or, and	the phone lines were	

		opened.					
		No public comment was provided.					
ii.	Drug class review presentation by Magellan (Prime).	Dr. Deoliveira recommended the Bo therapeutically equivalent.					
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Adashek moved to a therapeutically equivalent as prese Member Gonzalez seconded the mo A vote was taken, and the results w attendance (in favor, against, and a	lan (Prime) and Board from members in				
		<ul> <li>Mark Decerbo, Pharm.D., Chair</li> <li>Kate Ward, Pharm.D., Vice Chair</li> <li>Joseph Adashek, MD</li> <li>Mark Crumby, Pharm.D.</li> <li>Elizabeth Gonzalez, Pharm.D.</li> <li>Sapandeep Khurana, MD</li> <li>Isabella Niezborala, Pharm.D.</li> <li>Leana Ramirez, Pharm.D.</li> <li>Aditi Singh, MD</li> </ul>	Yes	No	Abst. □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □		
iv.	Presentation of recommendations for PDL inclusion by Magellan (Prime).	Dr. Deoliveira recommended movir ER tablet from preferred to non-pre	Dr. Deoliveira recommended moving cefaclor suspension and cefaclor ER tablet from preferred to non-preferred. She also recommended removing cefuroxime suspension from the PDL as it has been				
v.	Discussion by Board and action by Board for	Chairperson Decerbo moved to app presented by Magellan (Prime) and the motion.		• •	-		

approval of drugs for inclusion on the PDL.	A vote was taken, and the results we attendance (in favor, against, and a				
		Yes	No	Abst.	
	• Mark Decerbo, Pharm.D., Chair	$\times$			
	• Kate Ward, Pharm.D., Vice Chair			$\boxtimes$	
	• Joseph Adashek, MD	X			
	• Mark Crumby, Pharm.D.	X			
	• Elizabeth Gonzalez, Pharm.D.	X			
	Sapandeep Khurana, MD	X			
	• Isabella Niezborala, Pharm.D.	X			
	• Leana Ramirez, Pharm.D.	X			
	Aditi Singh, MD			$\boxtimes$	
<ul> <li>K. For Possible Action: Discussion and possible adoption of Bisphosphonates.</li> </ul>					
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone lines were opened.				
	No public comment was provided.				
ii. Drug class review presentation by Magellan (Prime).	Dr. Deoliveira recommended the Board consider the class clinically and therapeutically equivalent.				
iii. Discussion by Board and	Board Member Adashek moved to a				
action by Board to	therapeutically equivalent as presented by Magellan (Prime) and Board				
approve clinical/therapeutic	Member Gonzalez seconded the motion.				
equivalency of agents in	A vote was taken, and the results were as follows from members in				
class.	attendance (in favor, against, and al				

<ul> <li>Yes No Abst.</li> <li>Mark Decerbo, Pharm.D., Chair</li></ul>
Joseph Adashek, MD     D     D
Mark Crumby, Pharm.D.     D
Elizabeth Gonzalez, Pharm.D.     D
Sapandeep Khurana, MD     Sapandeep Khurana, MD
• Isabella Niezborala, Pharm.D. 🛛 🗆
• Leana Ramirez, Pharm.D. 🛛 🗆 🗆
Aditi Singh, MD     D     Z
<ul> <li>iv. Presentation of recommendations for PDL inclusion by Magellan (Prime).</li> <li>Dr. Deoliveira recommended moving ibandronate from non-preferred to preferred on the PDL. She also recommended adding risedronate (generic for Actonel®) to the PDL as preferred and risedronate (generic for Atelvia®) as non-preferred. She also recommended removing Boniva® and etidronate (generic for Didronel®) from the PDL as these drugs have been discontinued.</li> </ul>
v.Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.Board Member Adashek moved to approve the proposed changes as presented by Magellan (Prime) and Board Member Gonzalez seconded the motion.
A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):
Yes No Abst.
Mark Decerbo, Pharm.D., Chair
● Kate Ward, Pharm.D., Vice Chair □ □ ⊠
• Joseph Adashek, MD 🛛 🗆 🗆
Mark Crumby, Pharm.D.     I
● Elizabeth Gonzalez, Pharm.D. ⊠ □ □
• Sapandeep Khurana, MD 🛛 🗆 🗆

	Leana Ramirez, Pharm.D.	
	Aditi Singh, MD	
<ul> <li>Annual Review -Established</li> <li>Drug Classes without</li> <li>Proposed Changes.</li> </ul>		
i. Public Comment	Telephonic and web comment was called for, and the phone lines were opened.	
	Public comment was provided by Sam Brantman, Senior Medical Science Liaison with Insight Pharmaceuticals.	
	Public comment was provided by Christine Dube, pharmacist with medical affairs employed by AstraZeneca.	
	Public comment was provided by Ronnie DePue, Senior Director of Field Medical Affairs at Axsome Therapeutics.	
	Public comment was provided by William Rowe, nurse practitioner and Senior Medical Science Liaison with Intracellular Therapies.	
	Public comment was provided by Valerie D Ng, pharmacist representing the field medical affairs team at LEO Pharma.	
	Public comment was provided by Alexandra Scharer, pharmacist on the field health economics and outcomes research team at Bristol Myers Squibb.	
	Public comment was provided by Kierra Brown, pharmacist in medical outcomes liaison for UCB.	
ii. Board Members Comments	Comment was provided by Board Member Khurana.	
	Comment was provided by Chairperson Decerbo.	

iii. Discussion by E action by Board approve clinical/therape equivalency of class.	d to review the Atopic Dermatit the December meeting. Als eutic Camzyos® for placement in agents in Adashek motion to approve changes as presented by M Gonzalez seconded the mo A vote was taken, and the r	<ul> <li>Recommendation from the Board Members to Magellan (Prime) is to review the Atopic Dermatitis agents including Adbry® and Opzelura® at the December meeting. Also recommended reviewing Airsupra® and Camzyos® for placement in the Decembers meeting. Board member Adashek motion to approve the established drug classes without changes as presented by Magellan (Prime) and Board Member Gonzalez seconded the motion.</li> <li>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</li> </ul>				
		Yes	No	Abst.		
	Mark Decerbo, Pharm.D.,					
	Kate Ward, Pharm.D., Vice			$\square$		
	<ul> <li>Joseph Adashek, MD</li> </ul>					
	Mark Crumby, Pharm.E					
	Elizabeth Gonzalez, Pha					
	Sapandeep Khurana, N					
	<ul> <li>Isabella Niezborala, Phi</li> </ul>					
	<ul> <li>Leana Ramirez, Pharm.</li> </ul>					
	Aditi Singh, MD			$\boxtimes$		
M. Magellan (Prime) R		New Line Extens	ons			
	On The Horizon	On The Horizon				
	New cardiology drug: ac					
	-					
	New metabolic drug: go	vorestat				
N. Closing Discussion						
i. Public comment subject	s on any No public comments were	provided.				

ii. Date and location of the next meeting.	Date: December 10, 2024 Location: Courtyard by Marriott Las Vegas Convention Center 3275 Paradise Road, Las Vegas, NV, 89109	
iii. Adjournment	Chairperson Decerbo adjourned the meeting at 3:44 PM.	

## Attachment A – Members of the Public in Attendance

Greg Kitchens	Emory Fullington	Todd Dickerson	Larry L Curtis	Bethany Howell	Lee Stout
Melinda Turkington	Leslie Costalin	Hiten Patadia	Tina Hartmann	Deanna Darlington	Mark Germain
Sabrina Schnur	John Omick	Carin Hennessey	Brittany Aviles	William Rowe	Reina Rittman
Sam Brantman	Dominique Davis	Kent Douglas	Karen Ou	Terry Turner	Mandey Sohal
Nadine Kienhoefer	Ryan A Roa	Stuart Pappas	Valerie D Ng	Olivia Capperella	Aaron Girvin
Paul Boothman	Brent Fushimi	Justin May	Ben Skoog	Elisa Ashton [SCGUS]	Belz & Case Government
Christine Dube	Ronnie DePue	Lynda Finch	Kenneth Garcia,	Stuart Pappas	Affairs- Scribe by Rewatch
Kierra Brown	Peter Barrio	Shadi A. Ahmed	Ryan K. Bitton	Jason C Bott	
Mark Duerre	Maria Reyes	Shelly Nickerson	Georgette Dzwilewski	Carmen Hi	
Alexandra Sharer	Camille Kerr	Kylie Neale	Jennifer Tamburo	Brad Harrison	

#### Attachment B – Submitted Written Comment

Allergy and Asthma Center - Airsupra

FEM Womens Wellness-Rexulti

### The Skin Docs- Opzelura

Frontier Medical and Behavioral Center-Rexulti